BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BBCI To Manage Biocryst Pharmaceuticals' (BCRX) Phase II Clinical Trial Of Forodesine Hydrochloride (BCX-1777) In T-cell Leukemia


10/19/2005 5:08:42 PM

KANSAS CITY, Mo., June 10 /PRNewswire/ -- BBCI, an international contract research organization, announced that it is providing clinical trial management services to BioCryst Pharmaceuticals, Inc. for its recently initiated Phase IIa trial with forodesine hydrochloride, a purine nucleoside phosphorylase (PNP) inhibitor that is currently in clinical development for treatment of T-cell cancers. Forodesine hydrochloride, a small-molecule drug which causes biochemical changes that result in blocking of the T-cell's DNA synthesis machinery, recently received orphan drug designation from the U.S. Food and Drug Administration for treatment of T-cell non-Hodgkin's lymphoma.

The Phase II clinical trial being managed by BBCI is a multi-center, global, open-label study to determine the efficacy of long-term dosing with forodesine hydrochloride. The trial will be divided into two parts, Phase IIa and IIb. The Phase IIa study will evaluate response rate and duration of response in 20 patients with refractory T-cell leukemia who have failed or relapsed previous treatment. Assuming the clinical data from the first part of the trial is sufficiently positive, BioCryst expects to initiate a larger Phase IIb study of up to 100 patients at cancer centers in both the U.S. and Europe.

About BioCryst:

BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel drugs that block key enzymes essential for cancer, cardiovascular and autoimmune diseases, and viral infections. BioCryst integrates the necessary disciplines of biology, crystallography, medicinal chemistry and computer modeling to effectively use structure-based drug design to discover and develop small-molecule pharmaceuticals. For more information about BioCryst, please visit the company's web site at http://www.biocryst.com/ .

About BBCI:

BBCI is an international Contract Research Organization dedicated to delivering on-time, reliable clinical trial management services to clients around the world. BBCI has been providing quality results in managing Phase II-IV studies for more than 28 years and has extensive surveillance experience in every major therapeutic area, with more than 100,000 patients enrolled in studies during the past five years, with particular emphasis on late-stage drug development. More information about BBCI can be found at http://www.bbclinical.com/ , or by calling 1-800-366-8531.

BBCI

CONTACT: For more information about BBCI, Chris Blandin, Project Managerof BBCI, +1-816-421-6400, or chris.b@bbclinical.com ; or for more informationregarding this release, Rick Rhyner, Advertising Coordinator of RhycomStrategic Advertising, +1-816-471-4869, or rrhyner@rhycom.com



Read at BioSpace.com

   
Leukemia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES